Reports for APOTEX INC
Company Name APOTEX INC |
||
---|---|---|
Totals |
||
Shortage reports |
3367 |
|
Actual shortage: | 219 (7%) | |
Anticipated shortage: | 0 (0%) | |
Avoided shortage: | 10 (0%) | |
Resolved: | 3138 (93%) | |
Discontinuation Reports |
365 |
|
To be discontinued: | 24 (7%) | |
Discontinued: | 341 (93%) | |
Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
68 (28%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-NAPRO-NA | 275MG | TABLET | Resolved | 2022-06-06 | 2022-08-22 | 162077 |
APO-NAPRO-NA DS | 550MG | TABLET | Resolved | 2022-07-15 | 2022-08-24 | 164744 |
APO-NAPRO-NA DS | 550MG | TABLET | Resolved | 2023-05-26 | 2023-07-27 | 193215 |
APO-NAPRO-NA DS | 550MG | TABLET | Resolved | 2019-01-03 | 2019-02-08 | 71139 |
APO-NAPRO-NA DS TAB 550MG | 550MG | TABLET | Resolved | 2017-05-24 | 2018-10-05 | 11082 |
APO-NAPROXEN | 500MG | TABLET | Resolved | 2022-02-22 | 2022-03-11 | 155362 |
APO-NAPROXEN | 375MG | TABLET | Resolved | 2022-09-01 | 2022-11-20 | 168421 |
APO-NAPROXEN | 500MG | TABLET | Resolved | 2022-09-16 | 2022-11-26 | 169513 |
APO-NAPROXEN | 250MG | TABLET | Resolved | 2022-10-21 | 2022-11-11 | 172342 |
APO-NAPROXEN | 500MG | TABLET | Resolved | 2017-10-03 | 2018-03-01 | 24274 |
APO-NAPROXEN | 250MG | TABLET | Resolved | 2018-02-01 | 2018-04-05 | 37971 |
APO-NAPROXEN | 500MG | TABLET | Resolved | 2024-02-09 | 2024-04-26 | 219171 |
APO-NAPROXEN | 500MG | TABLET | Resolved | 2024-03-15 | 2024-06-21 | 222478 |
APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-08-04 | 2023-08-12 | 201171 |
APO-NAPROXEN | 375MG | TABLET | Resolved | 2023-09-07 | 2023-10-13 | 203849 |
APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-09-28 | 2023-11-10 | 205489 |
APO-NAPROXEN | 500MG | TABLET | Resolved | 2023-09-28 | 2023-11-10 | 205498 |
APO-NAPROXEN | 375MG | TABLET | Resolved | 2020-01-22 | 2020-02-21 | 103914 |
APO-NAPROXEN | 375MG | TABLET | Resolved | 2020-02-05 | 2020-02-21 | 105352 |
APO-NAPROXEN | 250MG | TABLET | Resolved | 2020-02-13 | 2020-02-28 | 106003 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |
APO-HYDROMORPHONE CR | 24MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110968 |
APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
APO-HYDROMORPHONE CR | 30MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110971 |
APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |